Diligence memo · auto-generated · as of July 2, 2026
Colossal Biosciences Inc.
Colossal Biosciences Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Colossal Biosciences Inc. operates in Biotech / Pharma, based in AUSTIN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Colossal Biosciences Inc. has raised $163M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $163M on 2023-01-27.
Most recent recorded round closed around 2023-01-27.
Valuation (modeled)modeled
Provath models Colossal Biosciences Inc. at approximately $2.8B (range $756M–$4.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.43× the median modeled value of Series D+ Biotech / Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (143% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 3.4 yr ago; this sector typically re-raises about every 15 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 97% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Alto Pharmacy Holdings, Inc., Vedanta Biosciences, Inc., Seismic Therapeutic, Inc., Vignette Bio, Inc., PharmaCann Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.